Conduit Pharmaceuticals announces 1-for-15 reverse stock split effective May 19, 2025

CDT Equity Inc.

1-for-15 reverse split effective May 19, 2025 at 5:00 p.m. ET; split-adjusted trading begins May 20 under ticker CDT.
Post-split outstanding shares reduced to approximately 755,900 from roughly 11.3 million pre-split.
No fractional shares issued; cash payment in lieu at closing price on May 19.
Par value unchanged at $0.0001; new CUSIP number 20678X 304; warrants and equity awards proportionally adjusted.
Stockholders approved reverse split at special meeting on May 5, 2025; board set exact ratio.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

CDT Equity Inc.: Filed certificate of amendment to Second Amended and Restated Certificate of Incorporation to effect a 1-for-15 reverse stock split (effective 2025-05-19).

Change: charter amendment
Effective: 2025-05-19

Exact text from the filing

On May 15, 2025, Conduit Pharmaceuticals Inc. (the “Company”) filed a certificate of amendment to the Company’s Second Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effectuate a 1-for-15 reverse stock split (the “Reverse Stock Split”) of the outstanding shares of the Company’s common stock (“Common Stock”).

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

CDT Equity Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-011183

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.